Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
SPARINE (Promazine Hydrochloride) is an oral concentrate antipsychotic approved in 1957 for psychiatric indications. It is a first-generation phenothiazine that works through dopamine antagonism in the central nervous system. This legacy agent has a long clinical history but limited current utilization.
This legacy product faces significant generic competition (30% competitive pressure) with minimal active commercial infrastructure, indicating limited team expansion opportunities.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Assessment of Intra-subject Variability in the Bioavailability of Chlorpromazine Hydrochloride
Working on SPARINE offers limited career upside given its LOE-approaching status and minimal commercial investment. This role suits professionals seeking stable, low-intensity work in legacy product stewardship rather than growth-oriented career advancement.
Worked on SPARINE at Thayer Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo